CTLA4 and neoplasm: Upon anti-CTLA-4 mAb treatment, the ratio of Teffs to Tregs was positively associated with treatment response, which is dependent on the presence of Fcγ receptor-expressing macrophages [58,59], suggesting the use of anti-CTLA-4 antibodies with enhanced FcγR binding profiles to achieve robust anti-tumor responses and improved survival [60].